Comparison of treatment effect between phase 2 and phase 3 trials in patients with inflammatory bowel disease.
Fiche publication
Date publication
septembre 2023
Journal
United European gastroenterology journal
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Wils P, Jairath V, Sands BE, Magro F, Reinisch W, Rubin D, Danese S, Baumann C, Peyrin-Biroulet L
Lien Pubmed
Résumé
The accumulation of multiple randomized controlled trials in the field of inflammatory bowel diseases provides an opportunity to compare treatment effects between phase 2 and 3 trials. We aimed to determine whether treatment effects observed in phase 3 investigating biologics and small molecule drugs differed from those in their preceding phase 2 trial.
Mots clés
Crohn's disease, biologics, inflammatory bowel disease, randomized controlled trial, ulcerative colitis
Référence
United European Gastroenterol J. 2023 09 5;: